Apremilast Offers a Strong Oral Choice for Psoriatic Arthritis Patients

Kenneth Gordon, Professor of Dermatology at Northwestern University, talks about the oral medication apremilast, recently approved for psoriatic arthritis. Apremilast offers a major benefit to patients — especially those who don’t want an injectable medication. Its response rates are high and it is very well tolerated.

Meetings

Healthcare Chief Medical Officer Forum	Alexandria, VA	November 13–14, 2014
Home Care Leadership Summit	Atlanta, GA	November 17–18, 2014
Customer Analytics & Engagement in Health Insurance	Chicago	December 4–5, 2014
Pharmaceutical and Biotech Clinical Quality Assurance Conference	Alexandria, VA	December 4–5, 2014
6th Semi-Annual Diagnostic Coverage and Reimbursement Conference	Boston	December 4–5, 2014
9th Semi-Annual Medical Device Coverage and Reimbursement Conference	San Diego	December 5, 2014
8th Annual Medical Device Clinical Trials Conference	Chicago	December 8–9, 2014
HealthIMPACT Southeast	Tampa, FL	January 23, 2015

Our other journal

P&T Journal for October 2014

Features

The Clinical Trial Model Is Up for Review

Pyrazinamide-Induced Hyperuricemia

Lung Cancer Research Is Taking On New Challenges

Medical Applications for 3D Printing: Current and Projected Uses

Pipeline Plus

Steady Progress on Parkinson’s Disease

Departments

Medication Errors

Telling True Stories Is an ISMP Hallmark

Prescription: Washington

FDA Accepts Its First Biosimilar Application

New Drugs/Drug News/New Medical Devices

Pharmaceutical Approval Update

Drug Forecast

Edoxaban: an Investigational Factor Xa Inhibitor

Apremilast Offers a Strong Oral Choice for Psoriatic Arthritis Patients